Showing results (741-750 of 963) with videos related to
Sort By:
Pageof 97
Nature Medicine|January 16, 2026
An oral, liver-restricted LXR inverse agonist for dyslipidemia: preclinical development and phase 1 trialXiaoxu Li, Giorgia Benegiamo, Archana Vijayakumar, et al.JHEP Reports : Innovation in Hepatology|December 30, 2025
Corrigendum to "Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study" [JHEP Reports 2025 7(10) 101516]Edward Gane, Ewa Janczewska, Tetsuo Takehara, et al.JHEP Reports : Innovation in Hepatology|September 8, 2025
Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN studyEdward Gane, Ewa Janczewska, Tetsuo Takehara, et al.Alimentary Pharmacology & Therapeutics|August 12, 2025
Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of TreatmentGrace Lai-Hung Wong, Edward Gane, Calvin Q Pan, et al.Nature Communications|April 23, 2026
Horizontal gene transfer and diploidy illuminate evolution and stress adaptation in oleaginous Scenedesmaceae (Chlorophyta)Linzhou Li, Hongli Wang, Xiayi Chen, et al.The Lancet. Oncology|January 24, 2025
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, studyRichard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, et al.BMC Nephrology|December 4, 2023
Impact of the COVID-19 pandemic on services for patients with chronic kidney disease: findings of a national survey of UK kidney centresLucy Mackintosh, Amanda Busby, Ken Farrington, et al.Journal of the International AIDS Society|September 7, 2023
Sexual and drug use risk behaviour trajectories among people treated for recent HCV infection: the REACT studyJoanne M Carson, Sebastiano Barbieri, Evan Cunningham, et al.The Lancet. Gastroenterology & Hepatology|June 13, 2020
Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label studyEric Lawitz, Charles S Landis, Steven L Flamm, et al.Genome Research|September 6, 2005
A microarray analysis of the rice transcriptome and its comparison to ArabidopsisLigeng Ma, Chen Chen, Xigang Liu, et al.Pageof 97